<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913379</url>
  </required_header>
  <id_info>
    <org_study_id>9785-CL-0006</org_study_id>
    <secondary_id>2011-000333-37</secondary_id>
    <nct_id>NCT01913379</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole</brief_title>
  <official_title>A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess possible drug-drug interactions between MDV3100 and gemfibrozil and MDV3100
      and Itraconazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetic profile of MDV3100 by Cmax (Maximum concentration)</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pharmacokinetic profile of MDV3100 by AUCinf (AUC extrapolated to infinity)</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pharmacokinetic profile of MDV3100 by AUC0-432h (AUC from the time of dosing to 432 hours post-dose)</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic profile of MDV3100</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
    <description>tmax (Time to attain Cmax), t1/2 (Apparent terminal elimination half life), Vz/F (Apparent volume of distribution during the terminal phase after extra vascular dosing) and CL/F(Apparent total body clearance after extra vascular dosing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic profile of the metabolites MDPC0001 and MDPC0002</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
    <description>Cmax, AUC0-432h, tmax, t1/2, and AUC0-inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of metabolite-to-parent ratios for MDV3100</measure>
    <time_frame>Day 1 through Day 53 (29 times)</time_frame>
    <description>This may additionally be reported to assess effects on particular enzyme pathways</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Gemfibrozil and gemfibrozil 1-O-Î²-glucuronide (Arm 2)</measure>
    <time_frame>Day 1 through Day 53 (50 times)</time_frame>
    <description>Cmax, C0h, Cmin, tmax, AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of itraconazole and hydroxyitraconazole (Arm 3)</measure>
    <time_frame>Day 1 through Day 53 (50 times)</time_frame>
    <description>Cmax, C0h, Cmin, tmax, AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by recording adverse events, laboratory assessments, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Day 1 through Day 53</time_frame>
    <description>In arm 3, liver function tests (AST, ALT, GGT, total bilirubin) will be done regularly during itraconazole dosing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Drug-Drug Interaction</condition>
  <arm_group>
    <arm_group_label>1: MDV3100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: MDV3100 and gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3: MDV3100 and itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDV3100</intervention_name>
    <description>Oral</description>
    <arm_group_label>1: MDV3100</arm_group_label>
    <arm_group_label>2: MDV3100 and gemfibrozil</arm_group_label>
    <arm_group_label>3: MDV3100 and itraconazole</arm_group_label>
    <other_name>ASP9785</other_name>
    <other_name>Xtandi</other_name>
    <other_name>enzalutamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
    <description>Oral</description>
    <arm_group_label>2: MDV3100 and gemfibrozil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Oral</description>
    <arm_group_label>3: MDV3100 and itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight of at least 65.0 kg and no greater than 85.0 kg.

          -  Body Mass Index (BMI) of at least 18.5 and no greater than 30.0 kg/m2.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to MDV3100, itraconazole, gemfibrozil, any
             components of the formulations used, or any history of liver toxicity with other
             drugs.

          -  Confirmed CYP2C8 PM status based on genotyping analysis.

          -  Any of the liver function tests above the upper limit of normal. A retest to confirm
             the result may be performed once.

          -  History of seizure, including any febrile seizure, loss of consciousness, or transient
             ischemia attack within 12 months prior to enrollment (Day 1 visit), or any condition
             that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation,
             head trauma with loss of consciousness requiring hospitalization).

          -  Any clinically significant history of asthma, eczema, any other allergic condition or
             previous severe hypersensitivity to any drug (excluding non-active hay fever).

          -  Abnormal pulse and/or blood pressure (BP) measurements at the pre-study visit as
             follows: Pulse &lt;40 or &gt;90 bpm; mean systolic BP &gt;140 mmHg ; mean diastolic BP &gt;90 mmHg
             (BP measurements taken in triplicate after subject has been resting in supine position
             for 5 min; pulse will be measured automatically).

          -  A QTc interval of &gt;430 ms after repeated measurements (consistently after duplicate
             measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmias or torsades de pointes, structural heart disease, or a family history of
             Long QT Syndrome (LQTS).

          -  Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months
             prior to admission to the Clinical Unit.

          -  Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Operation Senior Research Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>MDV3100</keyword>
  <keyword>Gemfibrozil</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Xtandi</keyword>
  <keyword>enzalutamide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

